|
Name |
Cyclosativene
|
Molecular Formula | C15H24 | |
IUPAC Name* |
1,2-dimethyl-8-propan-2-yltetracyclo[4.4.0.02,4.03,7]decane
|
|
SMILES |
CC(C)C1CCC2(C3C1C4C2(C4C3)C)C
|
|
InChI |
InChI=1S/C15H24/c1-8(2)9-5-6-14(3)10-7-11-13(12(9)10)15(11,14)4/h8-13H,5-7H2,1-4H3
|
|
InChIKey |
XBWACJDEQIZTPR-UHFFFAOYSA-N
|
|
Synonyms |
cyclosativene; (+)-Cyclosativene; 1,2-dimethyl-8-(propan-2-yl)tetracyclo[4.4.0.0?,?.0?,?]decane; 1,2,4-Metheno-1H-indene, octahydro-1,7a-dimethyl-5-(1-methylethyl)-, [1S-(1.alpha.,2.alpha.,3a.beta.,4.alpha.,5.alpha.,7a.beta.,8S*)]-; 22469-52-9; FT-0701660; (1S,2S,3aR,4R,5S,7aS,8R)-5-Isopropyl-1,7a-dimethyloctahydro-1H-1,2,4-(epimethanetriyl)indene; 1,2,4-Metheno-1H-indene, octahydro-1,7a-dimethyl-5-(1-methylethyl)-, (1S,2S,3aR,4R,5S,7aS,8R)-; 1,2.alpha.,4-Methenoindan, 3a.beta.,4.beta.,5,6,7,7a-hexahydro-5.alpha.-isopropyl-1.beta.,7a.beta.-dimethyl-
|
|
CAS | NA | |
PubChem CID | 519960 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 204.35 | ALogp: | 4.9 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 15 | QED Weighted: | 0.585 |
Caco-2 Permeability: | -4.63 | MDCK Permeability: | 0.00006350 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.012 |
30% Bioavailability (F30%): | 0.817 |
Blood-Brain-Barrier Penetration (BBB): | 0.73 | Plasma Protein Binding (PPB): | 95.94% |
Volume Distribution (VD): | 1.683 | Fu: | 3.41% |
CYP1A2-inhibitor: | 0.229 | CYP1A2-substrate: | 0.738 |
CYP2C19-inhibitor: | 0.196 | CYP2C19-substrate: | 0.955 |
CYP2C9-inhibitor: | 0.252 | CYP2C9-substrate: | 0.303 |
CYP2D6-inhibitor: | 0.015 | CYP2D6-substrate: | 0.351 |
CYP3A4-inhibitor: | 0.163 | CYP3A4-substrate: | 0.597 |
Clearance (CL): | 20.258 | Half-life (T1/2): | 0.073 |
hERG Blockers: | 0.051 | Human Hepatotoxicity (H-HT): | 0.224 |
Drug-inuced Liver Injury (DILI): | 0.047 | AMES Toxicity: | 0.022 |
Rat Oral Acute Toxicity: | 0.617 | Maximum Recommended Daily Dose: | 0.823 |
Skin Sensitization: | 0.165 | Carcinogencity: | 0.041 |
Eye Corrosion: | 0.017 | Eye Irritation: | 0.041 |
Respiratory Toxicity: | 0.937 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003118 | 0.464 | D04CSZ | 0.321 | ||||
ENC000535 | 0.439 | D0V8HA | 0.259 | ||||
ENC002553 | 0.414 | D0I2SD | 0.253 | ||||
ENC003050 | 0.410 | D06AEO | 0.244 | ||||
ENC005456 | 0.406 | D0U3GL | 0.244 | ||||
ENC001878 | 0.403 | D0M4WA | 0.242 | ||||
ENC003125 | 0.400 | D0Z4ZT | 0.242 | ||||
ENC001293 | 0.393 | D03ZTE | 0.242 | ||||
ENC005929 | 0.387 | D0G3SH | 0.242 | ||||
ENC005930 | 0.387 | D04SFH | 0.239 |